Is a sustained release formulation of bupivacaine using our TRANSDUR® technology to provide pain relief for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN).
View complete product pipeline
November 11, 2014DURECT Provides Update on POSIDUR™ Program
November 03, 2014DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs
October 27, 2014DURECT Provides Update on REMOXY® and POSIDUR™ Programs
October 24, 2014DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call